Nuvo receives $5.6 million investment from SAB

Guest Contributor
August 31, 2012

Mississauga ON-based Nuvo Research Inc has received $5.6 million from the German Development Bank of Saxony (SAB) for further development of WF10, its immune modulating drug to regulate the normal function of the immune system. Funded by the European Union and the Free State of Saxony, SAB is a standalone development bank with no commercial banking activities. In other news, Nuvo will receive $6 million in milestone payments related to its topical anesthetic cream Pliaglis, which provides topical local analgesia for superficial dermatological procedures. The payments will be made by Nuvo's marketing partner, Galderma SA and relates to three marketing licenses from EU countries….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.